Answers are grounded in this paper and cite their sources.
Significance Of the many receptors that were pharmacologically described during the 20th century, almost all were cloned by the end of the 1990s. A key exception is the σ 2 receptor, a potential therapeutic target for diseases as diverse as schizophrenia, Alzheimer’s disease, and cancer. Despite the development of a rich pharmacopeia, the unknown molecular identity of the receptor has crippled biological investigation. Here, we identify the σ 2 receptor as TMEM97, a membrane protein implicated in cancer and a binding partner of Niemann–Pick disease protein NPC1. Our results unite two fields of research, bringing the σ 2 receptor into the modern age of biological inquiry and providing the TMEM97 field with a rich pool of ligands and pharmacological tools.
No takes yet. Share an insight, caveat, or question.
Alon et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: